Toward the definition of immunosuppressive regimens with antitumor activity

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Organ transplantation requires immunosuppressive therapies, which increase cancer risk due to immune suppression and potential tumor-promoting effects of medications.
• Malignancy development is a significant concern for transplant recipients, necessitating a deeper understanding of immunosuppressant impacts on cancer cells.

Purpose of the Study:

• To compare the in vitro effects of four distinct immunosuppressive agents—cyclosporine, rapamycin, mycophenolic acid, and leflunomide—on the proliferation of various cancer cell lines and endothelial cells.
• To identify immunosuppressive agents with potential antitumor activities for optimizing transplant recipient care.

Main Methods:

• In vitro assessment of four immunosuppressive agents: cyclosporine, rapamycin, mycophenolic acid, and leflunomide.
• Evaluation of drug effects on the growth of human rhabdomyosarcoma, hepatocellular carcinoma, colorectal carcinoma, and human umbilical vein endothelial cells.

Main Results:

• Rapamycin, mycophenolic acid, and leflunomide demonstrated significant inhibition of tumor cell and endothelial cell growth at specified concentrations.
• Cyclosporine showed no significant impact on the in vitro growth of the tested tumor and endothelial cell lines.
• The degree of growth inhibition varied among the tested immunosuppressive agents.

Conclusions:

• Immunosuppressive agents like rapamycin, mycophenolic acid, and leflunomide possess both immunosuppressive and direct antitumor properties.
• Regimens incorporating rapamycin, mycophenolic acid, or leflunomide may be preferable in organ transplant recipients to mitigate the risk of malignancy development.
• Further research into the dual-acting properties of these immunosuppressants could lead to improved long-term outcomes for transplant patients.